Reynaldo Garcia on CML BCR-ABL Testing

All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.